Skip to main content
  • Effect of cardiac amyloidosis on outcomes in transcatheter aortic valve replacement in low-flow low-gradient aortic stenosis

    Aortic stenosis (AS) is the most prevalent valvular heart disease in developed countries, primarily affecting the elderly population [  ]. Its traditional hemodynamic assessment distinguishes between high-gradient AS and low-flow low-gradient (LF-LG) AS, the latter presenting a complex diagnostic and therapeutic challenge [  ,  ]. This paradoxical presentation complicates the decision-making process, particularly regarding the indication and timing for aortic valve replacement (AVR). Transcatheter aortic valve replacement (TAVR) has emerged as a revolutionary treatment for severe AS, particularly for those at intermediate to high surgical risk [  ].

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details